Telix Today Announces A Collaboration With Uniquest Pty Ltd (Uniquest), The Commercialisation Company Of The University Of Queensland (Uq), To Develop A Radiolabelled Molecule Targeting An Immune Checkpoint Protein. The Announcement Was Made At The Ausbiotech 2022 National Conference, Currently Being Held In Perth, Western Australia.Under The Agreement, Telix And Uniquest Will Work Together To Adapt And Refine An Undisclosed Targeting Peptide
